-
1.发明授权公开(公告)号：US11969459B2
公开(公告)日：2024-04-30
申请号：US16477878
申请日：2018-01-26
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto Tamai , Yoshiki Sawa , Shigeru Miyagawa , Takashi Kido , Takasumi Goto , Takehiko Yamazaki
Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.
-
2.发明授权公开(公告)号：US11826401B2
公开(公告)日：2023-11-28
申请号：US16477878
申请日：2018-01-26
Applicant: StemRIM Inc. , OSAKA UNIVERSITY
Inventor： Katsuto Tamai , Yoshiki Sawa , Shigeru Miyagawa , Takashi Kido , Takasumi Goto , Takehiko Yamazaki
Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.
-
3.发明授权公开(公告)号：US12084683B2
公开(公告)日：2024-09-10
申请号：US16702755
申请日：2019-12-04
Applicant: TERUMO KABUSHIKI KAISHA , OSAKA UNIVERSITY
Inventor： Fumiya Ohashi , Hiroko Iseoka , Yoshiki Sawa , Shigeru Miyagawa
CPC classification number: C12N5/0657 , A61K35/34 , C12N5/0093 , C12N5/0602 , C12N5/0603 , C12N5/0606 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/998 , C12N2506/45
Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.
-
公开(公告)号：US11124770B2
公开(公告)日：2021-09-21
申请号：US15594011
申请日：2017-05-12
Applicant: TERUMO KABUSHIKI KAISHA , OSAKA UNIVERSITY
Inventor： Hiroko Iseoka , Yoshiki Sawa , Shigeru Miyagawa , Satsuki Fukushima
Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.
-
公开(公告)号：US20210113464A1
公开(公告)日：2021-04-22
申请号：US16766992
申请日：2017-11-27
Applicant: Osaka University , Cardio Incorporated
Inventor： Yoshiki Sawa , Shigeru Miyagawa , Yoshiki Sakai , Yasuhiro Yanagi
IPC: A61K9/127 , A61K31/4406
Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US09597436B2
公开(公告)日：2017-03-21
申请号：US14429565
申请日：2013-09-13
Applicant: Osaka University , Nipro Corporation , Ono Pharmaceutical Co., Ltd.
Inventor： Yoshiki Sawa , Shigeru Miyagawa , Satsuki Fukushima , Atsuhiro Saito , Yoshiki Sakai , Kazuhisa Matsuda , Takayuki Maruyama
IPC: A61K31/16 , A61K31/4406 , A61K31/343 , A61K9/16 , A61K9/00 , A61L31/14 , A61L31/16
CPC classification number: A61L31/16 , A61F2/2481 , A61K9/0024 , A61K9/16 , A61K9/1647 , A61K31/343 , A61K31/4406 , A61K47/42 , A61L17/005 , A61L17/12 , A61L17/145 , A61L31/06 , A61L31/10 , A61L31/146 , A61L31/148 , A61L2300/412 , A61L2300/622 , A61L2430/20 , C08L89/00 , C08L89/06 , C08L67/04
Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.
-
公开(公告)号：US20160312188A1
公开(公告)日：2016-10-27
申请号：US14998446
申请日：2016-01-08
Applicant: OSAKA UNIVERSITY
Inventor： Akifumi Matsuyama , Hiroshi Komoda , Yoshiki Sawa , Yuzuru Kanakura
IPC: C12N5/071 , C12N5/077 , C12N5/0775
CPC classification number: C12N5/0676 , A61K35/12 , C12N5/0653 , C12N5/0667 , C12N5/0678 , C12N2500/25 , C12N2500/32 , C12N2500/33 , C12N2500/38 , C12N2501/115 , C12N2501/335 , C12N2503/02 , C12N2506/1384 , C12N2533/52 , G01N33/507
Abstract: A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on.
-
8.发明申请Advanced Heart Failure Treatment Material as Myocardial/Cardiovascular Regeneration Device 有权高级心力衰竭治疗材料作为心肌/心血管再生装置公开(公告)号：US20150231312A1
公开(公告)日：2015-08-20
申请号：US14429565
申请日：2013-09-13
Applicant: Osaka University , Nipro Corporation , Ono Pharmaceutical Co., Ltd.
Inventor： Yoshiki Sawa , Shigeru Miyagawa , Satsuki Fukushima , Atsuhiro Saito , Yoshiki Sakai , Kazuhisa Matsuda , Takayuki Maruyama
IPC: A61L31/16 , A61L31/14 , A61K9/00 , A61K9/16 , A61K31/4406 , A61K31/343
CPC classification number: A61L31/16 , A61F2/2481 , A61K9/0024 , A61K9/16 , A61K9/1647 , A61K31/343 , A61K31/4406 , A61K47/42 , A61L17/005 , A61L17/12 , A61L17/145 , A61L31/06 , A61L31/10 , A61L31/146 , A61L31/148 , A61L2300/412 , A61L2300/622 , A61L2430/20 , C08L89/00 , C08L89/06 , C08L67/04
Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.
Abstract translation: 提供了一种先进的心力衰竭治疗材料，作为心肌/心血管再生装置，可自我组装，可以通过商业化提高普遍性并在紧急情况下使用，无需细胞培养（无细胞），通过控制茎 对于顽固性心血管疾病，特别是晚期心力衰竭的基础治疗具有很高的治疗效果，其中不仅挽救生命，而且改善患者的生活质量（QOL）是迫切的问题。 先进的心力衰竭治疗材料包括药剂，用于药剂的药剂和心肌支持装置。
-
公开(公告)号：US20240082154A1
公开(公告)日：2024-03-14
申请号：US18491953
申请日：2023-10-23
Applicant: Osaka University , Cuorips Inc
Inventor： Yoshiki Sawa , Shigeru Miyagawa , Yoshiki Sakai , Yasuhiro Yanagi
IPC: A61K9/127 , A61K31/4406
CPC classification number: A61K9/127 , A61K9/1277 , A61K31/4406
Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
-
公开(公告)号：US20220323726A1
公开(公告)日：2022-10-13
申请号：US17641669
申请日：2020-09-08
Applicant: OSAKA UNIVERSITY
Inventor： Yoshiki Sawa , Masakazu Yagi , Yusuke Misumi
Abstract: To provide a catheter for aortic valvuloplasty in which it is possible to significantly increase the therapeutic effect despite being minimally invasive. The present invention provides a catheter for aortic valvuloplasty characterized by including: first to third balloons that can expand and contract due to supply of a fluid, it being possible to change the relative positional relationships of the first to third balloons; first to third shafts that connect to the first to third balloons at the tip and supply fluid to the first to third balloons to cause the first to third balloons to expand and contract independently of each other; and at least one wire that introduces the first to third balloons from outside the patient's body to the aortic valve.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.021 seconds)
